Intermittent and continuous imatinib in a human GIST xenograft model carrying<i>KIT</i>exon 17 resistance mutation D816H

Abstract

Imatinib delays GIST xenograft growth despite the presence of the D816H resistance mutation. The schedule of imatinib administration may influence tumour glucose uptake rate and metabolic rate.